Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR—final report from AFTER-SKI
Sign Up to like & getrecommendations! Published in 2021 at "Leukemia"
DOI: 10.1038/s41375-021-01173-w
Abstract: Discontinuation of tyrosine kinase inhibitor (TKI) treatment for chronic phase (CP) CML patients with a deep molecular response (DMR) has entered standard practice. This is based on numerous clinical studies showing that ~50% of patients… read more here.
Keywords: euro ski; cml; loss mmr; discontinuation ... See more keywords